E-Issn No : 2455-295X | Volume : 2 | Issue : 11 | Nov 2016

Total Page:16

File Type:pdf, Size:1020Kb

E-Issn No : 2455-295X | Volume : 2 | Issue : 11 | Nov 2016 Research Paper E-ISSN NO : 2455-295X | VOLUME : 2 | ISSUE : 11 | NOV 2016 POSOLOGICAL DOSE OF THERAPEUTICS OVER PROPHYLAXIS IN TOXICOLOGICAL SERENDIPITY Kinsuk Sarker 1 | Apurbo Sarker 2 | Arittra Ghosh 3 | Prof. Dr. Dhrubo Jyoti Sen 4 1 Department of Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Gujarat Technological University, Arvind Baug, Mehsana–384001, Gujarat, India. ABSTRACT Drug, any chemical substance that affects the functioning of living things and the organisms (such as bacteria, fungi and viruses) that infect them. Pharmacology, the science of drugs, deals with all aspects of drugs in medicine, including their mode of action, physical and chemical properties, metabolism, therapeutics and toxicity. The therapeutic index of a drug is the ratio between the dosage that causes a toxic/lethal effect and the dosage that causes a therapeutic effect. The term pharmacotherapy refers to the use of drugs for treating diseases, whereas pharmacology is the study of drug action on living systems. It is the interaction of the drug molecules and drug receptors that brings about a therapeutic effect. However, it is extremely essential to administer the drug in the right dose to achieve such an effect. If taken in large doses, certain drugs could cause adverse effects. Thus, in order to reap the benefits, it is essential to assess the right dose. Therapeutic drug monitoring (TDM) becomes essential to determine the dose at which a drug will be safe and effective, especially with those with a narrow therapeutic index (NTI). Also, monitoring might be required when the patient is affected by a medical condition that has an adverse effect on the clearance of NTI drugs. There's no denying the fact that drug metabolism could vary from person to person. Thus, the key to avoid drug-related problems is to consider the drug's therapeutic index and other relevant factors for ensuring safety. Therapeutic index (TI) refers to any of the several indices that are used for measuring a drug's safety. The most common TI is the ratio of the median lethal dose to the median effective dose of a drug. The formula for TI is: LD50/ED50. LD50 stands for median lethal dose and ED50 stands for median effective dose (therapeutic dose). LD50 refers to the dose that would produce a lethal effect in 50% of the population, whereas ED50 refers to the dose that will produce the desired therapeutic effect in 50% of the population. This index is commonly used to measure a drug's safety. The therapeutic index formula is: TD50/ED50. TD50 stands for the median toxic dose, whereas ED50 stands for the median effective dose. TD50 refers to the minimum drug dose that would produce a toxic effect in 50% of the population, whereas ED50 refers to the minimum drug dose that will produce the desired therapeutic effect in 50% of the population. Another related concept is that of therapeutic range (TR). TR is the range of doses/concentrations at which a therapeutic agent or drug produces a therapeutic response without causing any significant adverse effect in patients. It can be measured by: MEC/MTC. MEC stands for minimum effective concentration, whereas MTC stands for minimum toxic concentration. MEC is the minimum concentration of the drug that is required for achieving the therapeutic effect, whereas MTC is the minimum concentration at which toxicity occurs. Basically, if at a particular dosage, a drug is above MTC, it would cause adverse effects. Similarly, a drug below MEC will not produce the desired therapeutic response. Keywords: TDM, NTI, TI, ED50, ED95, LD50, ID50, IC50, TD50, LDLo, MEC, MTC, TD, TR, USFDA, OBD, MTD, Safety Ratio, USFDA, Protective index, Therapeutic window. on plasma exposure levels. In the early days of pharmaceutical INTRODUCTION toxicology, TI was frequently determined in animals as lethal A ratio that compares the blood concentration at which a drug dose of a drug for 50% of the population (LD50) divided by the becomes toxic and the concentration at which the drug is minimum effective dose for 50% of the population (ED50). effective is known as therapeutic index (TI). The larger the Today, more sophisticated toxicity endpoints are used.[1] therapeutic index (TI), the safer the drug is. If the TI is small (the difference between the two concentrations is very small), the drug must be dosed carefully and the person receiving the drug should be monitored closely for any signs of drug toxicity. The therapeutic index (TI) (also referred to as therapeutic window or safety window or sometimes as therapeutic ratio) is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes toxicity. Figure-1: Therapeutics and Prophylaxis Classically, in an established clinical indication setting of an Therapeutic Index=LD /ED in animal studies, or for humans, approved drug, TI refers to the ratio of the dose of drug that 50 50 Therapeutic Index=TD /ED . For many drugs, there are causes adverse effects at an incidence/severity not compatible 50 50 severe toxicities that occur at sub-lethal doses in humans and with the targeted indication (e.g. toxic dose in 50% of subjects, these toxicities often limit the maximum dose of a drug. A TD ) to the dose that leads to the desired pharmacological 50 higher therapeutic index is preferable to a lower one: a patient effect (e.g. efficacious dose in 50% of subjects, ED ). In 50 would have to take a much higher dose of such a drug to reach contrast, in a drug development setting TI is calculated based INTERNATIONAL EDUCATIONAL SCIENTIFIC RESEARCH JOURNAL 61 Research Paper E-ISSN NO : 2455-295X | VOLUME : 2 | ISSUE : 11 | NOV 2016 the toxic threshold than the dose taken to elicit the therapeutic the term in this regard would be ED50 of 95%. Notwithstanding, [4] effect. Generally, a drug or other therapeutic agent with a usage of the term ED95 has stuck in this context. narrow therapeutic range (i.e. having little difference between toxic and therapeutic doses) may have its dosage adjusted according to measurements of the actual blood levels achieved in the person taking it. This may be achieved through therapeutic drug monitoring (TDM) protocols. TDM is recommended for use in the treatment of psychiatric disorders with lithium due to its narrow therapeutic range.[2] An effective dose (ED) in pharmacology is the dose or amount of drug that produces a therapeutic response or desired effect in some fraction of the subjects taking it. ED=Effective Dose, TD=Toxic Dose, LD=Lethal Dose, TI=Therapeutic Index, TR=Therapeutic Ratio. Figure-2: Graphical plot of therapeutic index EFFECTIVE DOSE50: It has been stated that any substance MEDIAN TOXIC DOSE: In toxicology, the median toxic can be toxic at a high enough dose. The line between efficacy dose (TD50) of a drug or toxin is the dose at which toxicity and toxicity is dependent upon the particular patient, although occurs in 50% of cases. The type of toxicity should be specified the dose administered by a physician should fall into the for this value to have meaning for practical purposes. The predetermined therapeutic window of the drug. The importance median toxic dose encompasses the category of toxicity that is of determining the therapeutic range of a drug cannot be greater than half maximum effective concentration (ED50) but overstated. This is generally defined by the range between the less than the median lethal dose (LD50). However, for some minimum effective dose (MED) and the maximum tolerated highly potent toxins (ex. lofentanil, botulinum toxin) the dose (MTD). The MED is defined as the lowest dose level of a difference between the ED50 and TD50 is so minute that the pharmaceutical product that provides a clinically significant values assigned to them may be approximated to equal doses. response in average efficacy, which is also statistically Since toxicity need not be lethal, the TD50 is generally lower significantly superior to the response provided by the placebo. than the median lethal dose (LD50) and the latter can be Similarly, the MTD is the highest possible but still tolerable considered an upper bound for the former. However, since the dose level with respect to a pre-specified clinical limiting toxicity is above the effective limit, the TD50 is generally toxicity. In general, these limits refer to the average patient greater than the ED50. If the result of a study is a toxic effect that population. For instances in which there is a large discrepancy does not result in death, it is classified as this form of toxicity. between the MED and MTD, it is stated that the drug has a large Toxic effects can be defined differently, sometimes considering therapeutic window. Conversely, if the range is relatively the therapeutic effect of a substance to be toxic (such as with small, or if the MTD is less than the MED, then the chemotherapeutics) which can lead to confusion and contention pharmaceutical product will have little to no practical value. regarding a substance's TD50. Examples of these toxic The "median effective dose" is the dose that produces a quantal endpoints include cancer, blindness, anemia, birth defects, etc. effect (all or nothing) in 50% of the population that takes it Alternative definition: ED95 (when referring to non (median referring to the 50% population base). It is also depolarizing muscle relaxants) is the ED50 from a cumulative sometimes abbreviated as the ED , meaning effective dose, for log dose response curve where the quantum is a 95% reduction 50 in twitch height.[5] 50% of people receiving the drug. The ED50 is commonly used as a measure of the reasonable expectancy of a drug effect, but LETHAL DOSE: In toxicology, the lethal dose (LD) is an does not necessarily represent the dose that a clinician might indication of the lethality of a given substance or type use.
Recommended publications
  • 1: Clinical Pharmacokinetics 1
    1: CLINICAL PHARMACOKINETICS 1 General overview: clinical pharmacokinetics, 2 Pharmacokinetics, 4 Drug clearance (CL), 6 Volume of distribution (Vd), 8 The half-life (t½), 10 Oral availability (F), 12 Protein binding (PB), 14 pH and pharmacokinetics, 16 1 Clinical pharmacokinetics General overview General overview: clinical pharmacokinetics 1 The ultimate aim of drug therapy is to achieve effi cacy without toxicity. This involves achieving a plasma concentration (Cp) within the ‘therapeutic window’, i.e. above the min- imal effective concentration (MEC), but below the minimal toxic concentration (MTC). Clinical pharmacokinetics is about all the factors that determine variability in the Cp and its time-course. The various factors are dealt with in subsequent chapters. Ideal therapeutics: effi cacy without toxicity Minimum Toxic Concentration (MTC) Ideal dosing Minimum Effective Concentration (MEC) Drug concentration Time The graph shows a continuous IV infusion at steady state, where the dose-rate is exactly appropriate for the patient’s clearance (CL). Inappropriate dosing Dosing too high in relation to the patient’s CL – toxicity likely Minimum Toxic Concentration (MTC) Minimum Effective Concentration (MEC) Dosing too low in relation to the Drug concentration patient’s CL – drug may be ineffective Time Some reasons for variation in CL Low CL High CL Normal variation Normal variation Renal impairment Increased renal blood fl ow Genetic poor metabolism Genetic hypermetabolism Liver impairment Enzyme induction Enzyme inhibition Old age/neonate 2 General overview Clinical Pharmacokinetics Pharmacokinetic factors determining ideal therapeutics If immediate effect is needed, a loading dose (LD) must be given to achieve a desired 1 concentration. The LD is determined by the volume of distribution (Vd).
    [Show full text]
  • Virulence and Transcriptome Profile of Multidrug-Resistant Escherichia Coli from Chicken Received: 3 April 2017 Hafiz I.Hussain 1, Zahid Iqbal1,4, Mohamed N
    www.nature.com/scientificreports OPEN Virulence and transcriptome profile of multidrug-resistant Escherichia coli from chicken Received: 3 April 2017 Hafiz I.Hussain 1, Zahid Iqbal1,4, Mohamed N. Seleem3, Deyu Huang2, Adeel Sattar2, Haihong Accepted: 3 July 2017 Hao1 & Zonghui Yuan1,2 Published: xx xx xxxx Numerous studies have examined the prevalence of pathogenic Escherichia coli in poultry and poultry products; however, limited data are available regarding their resistance- and virulence-associated gene expression profiles. This study was designed to examine the resistance and virulence of poultryE. coli strains in vitro and in vivo via antibiotic susceptibility, biofilm formation and adhesion, and invasion and intracellular survivability assays in Caco-2 and Raw 264.7 cell lines as well as the determination of the median lethal dose in two-day old chickens. A clinical pathogenic multidrug-resistant isolate, E. coli 381, isolated from broilers, was found to be highly virulent in cell culture and 1000-fold more virulent in a chicken model than other strains; accordingly, the isolate was subsequently selected for transcriptome analysis. The comparative gene expression profile of MDRE. coli 381 and the reference human strain E. coli ATCC 25922 was completed with Illumina HiSeq. 2500 transcriptome analysis. Differential gene expression analysis indicates that there are multiple pathways involved in the resistance and virulence of this highly virulent strain. The results garnered from this study provide critical information about the highly virulent MDR E. coli strain of poultry origin and warrant further investigation due to its significant threat to public health. Escherichia coli is a Gram-negative bacterium that displays a wide range of genomic diversity.
    [Show full text]
  • Narrow Therapeutic Index
    Therapeutic Drug Monitoring Some drugs have a narrow therapeutic index, which means that there is only a small difference between the minimum effective concentrations and the minimum toxic concentrations in the blood. With such drugs, small increases in dose or in blood/serum concentrations could lead to toxic effects. Therapeutic drug monitoring may help to optimise treatment in cases where there is a firm relationship between the toxic/therapeutic effects and drug concentrations in whole blood/serum. A therapeutic interval has been defined for the drugs in the following tables. This is the minimum effective and maximum safe concentration for compliant patients, on stabilised regimens. Levels within these limits should prove satisfactory in most cases. Whole blood or serum drug concentrations are useful for determining patient compliance or for assessing whether or not: 1. adequate concentrations are being achieved or, 2. potentially toxic concentrations are being reached. Depending on clinical conditions, dosage adjustments may be needed when levels are outside the therapeutic interval. Therapeutic drug monitoring can also be useful when changes are made to other medications that could affect serum or whole blood concentrations and lead to a reduction in effectiveness or increased toxicity. Although plasma drug concentrations and the therapeutic interval are useful in evaluating drug therapy, they should not be the only criteria on which treatment is based. Always remember to treat the patient, not the level. Drug concentrations in serum or whole blood are only meaningful if the correct procedures are followed regarding the timing of specimens and selection of sample tube. It is vitally important to note the exact time the sample is taken and when each dose of the drug is given.
    [Show full text]
  • Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
    Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications,
    [Show full text]
  • Principle of Pharmacodynamics
    Principle of pharmacodynamics Dr. M. Emamghoreishi Full Professor Department of Pharmacology Medical School Shiraz University of Medical Sciences Email:[email protected] Reference: Basic & Clinical Pharmacology: Bertrum G. Katzung and Anthony J. Treveror, 13th edition, 2015, chapter 20, p. 336-351 Learning Objectives: At the end of sessions, students should be able to: 1. Define pharmacology and explain its importance for a clinician. 2. Define ―drug receptor‖. 3. Explain the nature of drug receptors. 4. Describe other sites of drug actions. 5. Explain the drug-receptor interaction. 6. Define the terms ―affinity‖, ―intrinsic activity‖ and ―Kd‖. 7. Explain the terms ―agonist‖ and ―antagonist‖ and their different types. 8. Explain chemical and physiological antagonists. 9. Explain the differences in drug responsiveness. 10. Explain tolerance, tachyphylaxis, and overshoot. 11. Define different dose-response curves. 12. Explain the information that can be obtained from a graded dose-response curve. 13. Describe the potency and efficacy of drugs. 14. Explain shift of dose-response curves in the presence of competitive and irreversible antagonists and its importance in clinical application of antagonists. 15. Explain the information that can be obtained from a quantal dose-response curve. 16. Define the terms ED50, TD50, LD50, therapeutic index and certain safety factor. What is Pharmacology?It is defined as the study of drugs (substances used to prevent, diagnose, and treat disease). Pharmacology is the science that deals with the interactions betweena drug and the bodyor living systems. The interactions between a drug and the body are conveniently divided into two classes. The actions of the drug on the body are termed pharmacodynamicprocesses.These properties determine the group in which the drug is classified, and they play the major role in deciding whether that group is appropriate therapy for a particular symptom or disease.
    [Show full text]
  • Evaluation of the Anticonvulsant Activity of the Seed Acetone Extract of Ferula Gummosa Boiss
    Journal of Ethnopharmacology 82 (2002) 105Á/109 www.elsevier.com/locate/jethpharm Evaluation of the anticonvulsant activity of the seed acetone extract of Ferula gummosa Boiss. against seizures induced by pentylenetetrazole and electroconvulsive shock in mice Mohammad Sayyah a,*, Ali Mandgary a, Mohammad Kamalinejad b a Department of Physiology and Pharmacology, Institute Pasteur of Iran, Tehran, Iran b Department of Pharmacognosy, Faculty of Pharmacy, Shaheed Beheshti University of Medical Sciences, Tehran, Iran Received 6 February 2002; received in revised form 11 May 2002; accepted 6 June 2002 Abstract Ferula gummosa Boiss. (Apiaceae) which has been used as an antiepileptic remedy in Iranian traditional medicine was evaluated for anticonvulsant activity against experimental seizures. The seed acetone extract of F. gummosa protected mice against tonic convulsions induced by maximal electroshock (the median effective dose [ED50]/198.3 mg/kg) and especially by pentylenetetrazole (ED50 /55 mg/kg). Neurotoxicity (sedation and motor impairment) of the extract was assessed by the rotarod test and the median toxic dose (TD50) value of 375.8 mg/kg was obtained. Preliminary phytochemical analysis showed the presence of terpenoids and alkaloids in the extract. The acceptable acute toxicity of the extract recommends further studies to determine the mechanism(s) and compound(s) involved in the anticonvulsant activity. # 2002 Elsevier Science Ireland Ltd. All rights reserved. Keywords: Ferula gummosa; Seizure; Maximal electroshock; Pentylenetetrazole 1. Introduction several seed extracts of F. gummosa against seizures induced by maximal electroshock (MES) or pentylene- Ferula gummosa Boiss. (Apiaceae) is a perennial plant tetrazole (PTZ). In order to evaluate the therapeutic native to central Asia, growing in the northern and value and safety, the neurotoxicity (sedation and motor western parts of Iran (Zargari, 1989).
    [Show full text]
  • Prof. Hanan Hagar Quantitative Aspects of Drugs
    Quantitative aspects of drugs Prof. hanan Hagar Ilos Determine quantitative aspects of drug receptor binding. Recognize concentration binding curves. Identify dose response curves and the therapeutic utility of these curves. Classify different types of antagonism QUANTIFY ASPECTS OF DRUG ACTION Bind Initiate Occupy Activate D + R D R DR* RESPONSE[R] Relate concentration [C] of D used (x- axis) Relate concentration [C] of D used (x- to the binding capacity at receptors (y-axis) axis) to response produced (y-axis) Concentration-Binding Curve Dose Response Curves AFFINITY EFFICACY POTENCY Concentration binding curves Is a correlation between drug concentration [C] used (x- axis) and drug binding capacity at receptors [B] (y-axis). i.e. relation between concentration & drug binding Concentration-Binding curves are used to determine: oBmax (the binding capacity) is the total density of receptors in the tissues. oKD50 is the concentration of drug required to occupy 50% of receptors at equilibrium. oThe affinity of drug for receptor The higher the affinity of D for receptor the lower is the KD i.e. inverse relation Concentration-Binding Curve (Bmax): Total density of receptors in the tissue K D KD (kD )= [C] of D required to occupy 50% of receptors at equilibrium Dose -response curves o Used to study how response varies with the concentration or dose. o Is a correlation between drug concentration [D] used (x- axis) and drug response [R] (y-axis). o i.e. relation between concentration & Response TYPES of Dose -response curves Graded dose-response curve Quantal dose-response curve (all or none). Graded Dose-response Curve o Response is gradual o Gradual increase in response by increasing the dose (continuous response).
    [Show full text]
  • L. Gel Against Sulphur Mustard- Induced Systemic Toxicity and Skin Lesions
    Research Paper Protective effect of Aloe vera L. gel against sulphur mustard- induced systemic toxicity and skin lesions G. Anshoo, S. Singh, A.S. Kulkarni, S.C. Pant, R. Vijayaraghavan ABSTRACT Objective: Sulphur mustard (SM), chemically 2,2'-dichloro diethyl sulphide, is an incapacitating and extremely toxic chemical warfare agent, and causes serious blisters on contact with human skin. SM forms sulphonium ion in the body that alkylates DNA and several other macromolecules, and induces oxidative stress. The aim of this study was to evaluate the protective effect of Aloe vera Defence Research L. gel against SM-induced systemic toxicity and skin lesions. and Development Materials and Methods: Aloe vera gel was given (250, 500 and 1000 mg/kg) orally to mice as three Establishment, doses, one immediately after SM administration by percutaneous route, and the other two doses on Gwalior – 474002. the next two days. Protective index was calculated with and without Aloe vera gel treatment. Aloe India vera gel was also given orally as three doses with 3 LD50 SM and the animals were sacrificed for Received: 8.7.2004 biochemical and histological evaluation, 7 days after SM administration. In another set of experi- Revised: 20.9.2004 ment Aloe vera gel was liberally applied on the SM administered skin site and the animals were Accepted: 29.9.2004 sacrificed after 14 days to detect its protective effect on the skin lesions induced by SM. Results: The protection given by Aloe vera gel was marginal. 1000 mg/kg dose of Aloe vera gel gave a protection index of 2.8.
    [Show full text]
  • Oecd Guideline for the Testing of Chemicals
    Draft November 2009 OECD GUIDELINE FOR THE TESTING OF CHEMICALS PROPOSAL FOR A NEW TEST GUIDELINE 223 Avian Acute Oral Toxicity Test INTRODUCTION 1. This test guideline describes procedures designed to estimate the acute oral toxicity of substances to birds, and it provides three testing options: (1) limit dose test, (2) LD50-slope test, and (3) LD50-only test. The LD50-slope and LD50-only options are sequential testing procedures. The test method selected will depend on whether or not a definitive median dose (LD50) and slope of the dose-response curve are both needed. Sequential testing procedures target the placement of doses and match the precision of the endpoint with the precision required. These sequential procedures were designed to minimise the numbers of birds used. A computer programme is available to aid the placement of doses and estimate the LD50, slope and confidence limits. 2. Development of this test guideline began at the SETAC/OECD Workgroup on avian toxicity testing following a workshop held in Pensacola, Florida, United States, in 1994 (1) with subsequent open SETAC and closed OECD Expert Group meetings in Europe and the United States to develop and optimise the sequential testing design. The sequential testing design has been developed with extensive statistical validation (2). INITIAL CONSIDERATIONS 3. The information required by different hazard assessment schemes may vary considerably. To satisfy these various needs, the following three tests are described: Limit dose test – This is the preferred test when toxicity is expected to be low and lethality is unlikely at the limit dose. The limit dose must be adequate for assessment purposes, and it is usually 2000 mg/kg-bwt.
    [Show full text]
  • Importance of ADME and Bioanalysis in the Drug Discovery
    alenc uiv e & eq B io io B a f v o a i l l a Journal of a b Vuppala et al., J Bioequiv Availab 2013, 5:4 n r i l i u t y o DOI: 10.4172/jbb.10000e31 J ISSN: 0975-0851 Bioequivalence & Bioavailability EditorialResearch Article OpenOpen Access Access Importance of ADME and Bioanalysis in the Drug Discovery Pradeep K Vuppala1*, Dileep R Janagam2 and Pavan Balabathula2 1Preclinical Pharmacokinetics Shared Resource, St. Jude Children’s Research Hospital, Memphis, TN, USA 2University of Tennessee Health Sciences Center, Memphis, TN, USA Editorial Bioanalytical support plays a vital role during the lead optimization stages. The major goal of the bioanalysis is to assess the over-all The hunt for new drugs can be divided into two stages: discovery ADME characteristics of the new chemical entities (NCE’s). Arrays and development. Drug discovery includes generating a hypothesis of of bioanalytical methods are required to completely describe the the target receptor for a particular disorder and screening the in vitro pharmacokinetic behavior in laboratory animals as well as in humans and/or in vivo biological activities of the new drug candidates. Drug [7]. Bioanalytical tools can play a significant role for the progress development involves the assessment of efficacy and toxicity of the new in drug discovery and development. Physiologic fluids such as blood, drug candidates. serum, plasma, urine and tissues are analyzed to determine the absorption and disposition of a drug candidate administered to a test To aid in a discovery program, accurate data on pharmacokinetics animal [8].
    [Show full text]
  • Factors Affecting Drug Response2
    Types of drug concentration– response relationship A. Graded drug concentration-Response Relationships As the dose of a drug is increased, the response (effect) of the tissue or organ is also increased. The efficacy (Emax) and potency (ED50) parameters are derived from these data. 112 GRADED DOSE- RESPONSE CURVE QUANTAL DOSE- RESPONSE CURVE 113 B. Quantal or all or none dose response relation ship. The Plot of the fraction of the population that responds at each dose of the drug versus the log of the dose administered. responses follow all or none phenomenon – that means the individual of the responding system either respond to their maximum limit or not at all to a dose of drug and there is no gradation of response. population studies. relates dose to frequency of effect . The median effective (ED50), median toxic (TD50) ,and median lethal doses (LD50) are extracted from experiments carried out in this manner. 114 Median effective dose (ED50):the dose at which 50% of individuals exhibit the specified quantal effect. Median toxic dose (TD50) :the dose required to produce a particular toxic effect in 50% of animals. Median lethal dose (LD50): is the lethal dose that causes death in 50% animal under experiment. 115 119 1. Excretion - Alteration of urine PH. e.g. Phanobarbitone + NaHCo3 - Alteration of active tubular secretion e.g. Probenecid + peincillin. II – Pharmcodynamic interaction - It occurs by modification of pharmacological response of one drug by another without altering the concentration of the drug in the tissue or tissue fluid. 1. Additive – Occurs when the combined effect of two drugs is equal to the sum of the effects of each agent given alone.
    [Show full text]
  • Multidisciplinary Approaches to Modern Therapeutics: Joining Forces for a Healthier Tomorrow
    Available Online at www.jptcp.com www.cjcp.ca/ ABSTRACTS / RÉSUMÉS Multidisciplinary Approaches to Modern Therapeutics: Joining Forces for a Healthier Tomorrow May 24-27, 2011 Montreal, QC Canadian Society of Pharmacology and Therapeutics La Société canadienne de Pharmacologie et de Therapeutique J Popul Ther Clin Pharmacol Vol 18(2):e315-e363; May 22, 2011 e315 © 2011 Canadian Society of Clinical Pharmacology and Therapeutics. All rights reserved. 2011 CSPT ANNUAL CONFERENCE - ABSTRACTS Contents (Presenters are underlined) Oral Presentations May 26, 2011……………………………………………………………………………..e317 Poster Presentations May 25, 2011……………………………………………………………………………...e320 Poster Presentations May 26, 2011………………………………………………………………………………e338 e316 J Popul Ther Clin Pharmacol Vol 18 (2):e315-e363; May 22, 2011 © 2011 Canadian Society of Clinical Pharmacology and Therapeutics. All rights reserved. 2011 CSPT ANNUAL CONFERENCE - ABSTRACTS ORAL PRESENTATIONS 1Department of Physiology and Pharmacology and 2 THURSDAY - MAY 26, 2011 Division of Clinical Pharmacology, Department of Medicine, The University of Western Ontario, London, Ontario, Canada 1 Corresponding Author: [email protected] Effect of human equilibrative nucleoside Conflict of Interest: None declared transporter 1 (hENT1) expression on adenosine production from neurons Background: The HMG-CoA reductase inhibitors, or Chu S, Parkinson FE statins, are widely prescribed to reduce cardiovascular Department of Pharmacology and Therapeutics, disease risk. There is considerable interindividual University of Manitoba, Winnipeg, Canada variation in statin exposure and response arising from Corresponding Author: [email protected] variability in both transport and metabolism. Conflict of Interest: None declared Objective: Our aim was to better understand the in vivo relevance of the organic anion-transporting Background: Adenosine is produced in brain under polypeptide (OATP) 1B family to atorvastatin (ATV), ischemic conditions.
    [Show full text]